• Corpus ID: 31121280

Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence

@article{Dooley2016BuprenorphinenaloxoneUI,
  title={Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence},
  author={Joe Dooley and Lianne Gerber-Finn and Irwin Antone and Jonathan Guilfoyle and Brittany Blakelock and Jazmyn Balfour-Boehm and Wilma M. Hopman and Naana Afua Jumah and Len Kelly},
  journal={Canadian Family Physician},
  year={2016},
  volume={62}
}
Objective To examine the maternal course and neonatal outcomes for women using buprenorphine-naloxone for opioid dependence in pregnancy. Design Retrospective cohort study comparing outcomes for the group of pregnant patients exposed to buprenorphine-naloxone with outcomes for those exposed to other narcotics and those not exposed to narcotics. Setting Northwestern Ontario obstetric program. Participants A total of 640 births in an 18-month period from July 1, 2013, to January 1, 2015. Main… 
cfp.ca
17 Citations
Highly Influential Citations
1
Background Citations
3

Tables from this paper

17 Citations

Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study.

Compared with buprenorphine monotherapy, the combined bupenorphine and naloxone product was an acceptable alternative pharmacologic treatment for opioid use disorder during pregnancy.

Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis.

Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature

It is demonstrated that buprenorphine-naloxone is a safe and effective opioid agonist treatment for pregnant people with OUD and patients and clinicians may be reassured about the use of this medication during pregnancy.

Opioid Agonist to Buprenorphine Cross-titration During Pregnancy: A Case Report

This case demonstrated how one pregnant person with chronic pain on opioid therapy but not meeting diagnostic criteria for opioid use disorder safely transitioned from full-μ agonist opioids to buprenorphine without precipitating withdrawal or adverse perinatal outcomes.

Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations

Maternal opioid use disorder and neonatal abstinence syndrome in northwest Ontario: a 7-year retrospective analysis.

  • J. DooleyGareth Ryan L. Kelly
  • Medicine
    Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la medecine rurale : le journal officiel de la Societe de medecine rurale du Canada
  • 2018
Despite the continually increasing rates of opioid exposure in pregnancy, rates of NAS decreased annually and were substantially lower than those of the North West Local Health Integration Network and the regional LHIN.

Using buprenorphine to treat neonatal abstinence syndrome: a quality improvement study

To assess if treating neonatal abstinence syndrome with sublingual buprenorphine (SLB) would decrease the mean duration of therapy (DOT) and length of birth hospital stay (LOS), a quality improvement study using plan-do-study-act (PDSA) cycles was utilized.

Management and monitoring of opioid use in pregnancy

Buprenorphine is suggested as first‐line therapy for pregnant women with opioid use to replace the continued use of opioids or detoxification and to minimize risk of fetomaternal opioid exposure.

Treating perinatal opioid use disorder in rural settings: Challenges and opportunities.

No. 349-Substance Use in Pregnancy.

  • A. OrdeanSuzanne M WongL. Graves
  • Medicine, Political Science
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • 2017

26 References

Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.

Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy.

Buprenorphine and Naloxone Compared With Methadone Treatment in Pregnancy

In a cohort of pregnant patients treated with either methadone or buprenorphine and naloxone in pregnancy, newborns exposed to maternal buPrenorphines and nAloxone had less frequent neonatal abstinence syndrome.

Neonatal abstinence syndrome after methadone or buprenorphine exposure.

A comparison of the 131 neonates whose mothers were followed to the end of pregnancy according to treatment group showed that the former group required significantly less morphine, which is consistent with the use of buprenorphine as an acceptable treatment for opioid dependence in pregnant women.

Methadone and Buprenorphine for the Management of Opioid Dependence in Pregnancy

For a full remission of opioid addiction to be sustainable, both post-partum and across the lifespan, treatment providers must not rely solely on medication to treat their patients but should also utilize women-specific comprehensive treatment models that address the underlying multifaceted complexities of their patient’s lives.

Opioid Detoxification in Pregnancy

Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis.

Prenatal BMT versus MMT may improve neonatal outcomes, but bias may contribute to this protective association, and further evidence is needed to guide treatment choices.

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes

Preliminary findings suggest no significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy, however, further research should examine possible differences.

Narcotic tapering in pregnancy using long-acting morphine: an 18-month prospective cohort study in northwestern Ontario.

In many patients, long-acting morphine preparations can be safely used and tapered in pregnancy, with a subsequent decrease in observed neonatal withdrawal symptoms, which is equivalent to those of the nonexposed pregnancies.

A Case Series of Buprenorphine/Naloxone Treatment in a Primary Care Practice

Feelings of feasibility and safety of a low-cost buprenorphine/naloxone home induction protocol employed by generalists are demonstrated and concurrent treatment of multiple comorbidities conforms with the patient-centered medical home ideal.

Narcotic-exposed neonates in a First Nations population in northwestern Ontario: incidence and implications.

Narcotic abuse during pregnancy is a considerable problem in First Nations communities in northwestern Ontario and community-based initiatives need to be developed to address this issue, and medical and nursing staff need to develop surveillance, assessment, and therapeutic responses.